

D1 proviso that said agent does not comprise H<sub>2</sub>S.

Cancel Claim 6.

Amend Claim 10 to be as follows:

D2 10. (Amended) A method for treating a pulmonary disorder associated with depletion of the S-nitrosoglutathione pool in the lung or depletion of the glutathione pool in the lung or production of reactive oxygen species in the lung in a patient having such disorder which comprises delivering into the lungs of said patient as a gas, a therapeutically effective amount of an agent, which causes repletion or increase of the S-nitrosoglutathione pool in the lung or protects against toxicity where glutathione is depleted in the lung or where reactive oxygen species are increased in the lung and does so independently of reaction with oxygen, with the proviso that when said agent comprises H<sub>2</sub>S, the H<sub>2</sub>S is administered at a dosage of 0.1 to 100 ppm in nitrogen.

Cancel Claim 12.

Please add Claims 13-16 as follows:

D3 --13. The method of Claim 10 where the H<sub>2</sub>S is administered at a dosage of 0.1 to 10 ppm in nitrogen.

--14. A method for treating a pulmonary disorder associated with depletion of the S-nitrosoglutathione pool in the lung or depletion of the glutathione pool in the lung or production of reactive oxygen species in the lung in a patient having such disorder which comprises delivering into the lungs of said patient as a gas, a therapeutically effective amount of an agent, which causes repletion or increase of the S-nitrosoglutathione pool in the lung or protects against toxicity where glutathione is depleted in the lung or where reactive oxygen species are increased in the

lung and does so independently of reaction with oxygen, with the proviso that said pulmonary disorder is not asthma.

*D3*  
--15. The method of Claim 14 where the disorder is selected group consisting of pulmonary hypertension including persistent pulmonary hypertension of the newborn, adult respiratory distress syndrome, pneumonia, interstitial lung diseases including pulmonary fibrosis, and cystic fibrosis.

--16. The method of Claim 15 where the agent comprises H<sub>2</sub>S.--

#### Remarks

As a result of this amendment, Claims 1-5, 7-11 and 13-16 are in the case.

Claim 1 has been amended to be Claim 12 in independent form.

Claim 6 has been canceled as being inconsistent with Claim 1 as amended.

Claim 10 has been amended to be in independent form.

Claim 12 has been canceled as being redundant in view of the amendment herewith to Claim 1.

Claims 13-16 are new claims.

Claim 13 depends from amended Claim 1 and has an upper limit for H<sub>2</sub>S of 10 ppm. Basis is submitted to be found in Example X at page 15 and in In re Wertheim, 191 U.S.P.Q. 90 (C.C.P.A. 1978) and in McLaughlin v. Roberts, 197 U.S.P.Q. 831 (Bd. App. 1978) which hold that description of a range includes description of a specific level with the range even though the specific level is not literally disclosed.

Basis for new Claims 14 and 15 is submitted to be found in In re Johnson, 194 U.S.P.Q. 187, 196 (C.C.P.A. 1977) and in the application as filed at page 7, line 20 - page 8, line 15.